Generic Name |
Brand Name |
Breast cancer type |
Breast cancer stage |
Where in the drug approval process is this treatment |
Abemaciclib |
Verzenio |
HR+, HER2- |
Stage IV (metastatic) |
Health Canada - Approved |
Abemaciclib |
Verzenio |
HR+, HER2- |
Stage 0, I, II, III |
Listed on Provincial Drug Formulary |
Abemaciclib (with an Aromatase Inhibitor/Non-Steroidal Aromatase Inhibitor ) |
Verzenio (with an Aromatase Inhibitor/Non-Steroidal Aromatase Inhibitor ) |
HR+, HER2- |
Stage IV (metastatic) |
Health Canada - Approved |
Abemaciclib (with fulvestrant) |
Verzenio (with fulvestrant) |
HR+, HER2- |
Stage IV (metastatic) |
PCPA - Under Review |
Abemaciclib with endocrine therapy |
Verenzio |
HR+, HER2- |
Stage 0, I, II, III |
PCPA - Approved; Provincial Review Ongoing |
Alpelisib |
Piqray |
HR+, HER2- |
Stage IV (metastatic) |
Health Canada - Approved |
Anastrozole |
Arimidex; various brand names |
HR+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Capecitabine |
Xeloda; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Capivasertib |
Truqap |
HR+, HER2- |
Stage IV (metastatic) |
PCPA - Under Review |
Carboplatin |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Cisplatin |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Cyclophosphamide |
Procytox; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Docetaxel |
Taxotere; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Doxorubicin |
Adriamycin; Myocet; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Epirubicin |
Pharmorubicin; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Eribulin |
Halaven |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Everolimus |
Afinitor |
HR+, HER2- |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Exemestane |
Aromasin; various brand names |
HR+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Fluorouracil |
Actikerall; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Fulvestrant |
Faslodex |
HR+ |
Stage IV (metastatic) |
Health Canada - Approved |
Gemcitabine |
Gemzar; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Goserelin 10.8mg |
Zoladex LA |
HR+ |
Stage 0, I, II, III, Stage Ib, II, III, Stage IV (metastatic) |
Health Canada - Approved |
Goserelin 3.6mg |
Zoladex |
HR+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Letrozole |
Femara; various brand names |
HR+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Leuprolide |
Lupron |
HR+ |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Megestrol |
Various brand names |
HR+ |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Methotrexate |
Metoject; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Mitoxantrone |
various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Neratinib |
Nerlynx |
HR+, HER2+ |
Stage 0, I, II, III |
Health Canada - Approved |
Olaparib |
Lynparza |
HR+, HER2-, Triple Negative, BRCA |
Stage IV (metastatic) |
Health Canada - Approved |
Olaparib |
Lynparza |
HR+, HER2-, Triple Negative, BRCA |
Stage 0, I, II, III |
Listed on Provincial Drug Formulary |
Paclitaxel |
Taxol; various brand names |
HR+, HER2-, HER2+, Triple Negative |
Stage 0, I, II, III, Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Paclitaxel-nab |
Abraxane |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Palbociclib (plus Aromatase Inhibitor/Non-Steroidal Aromatase Inhibitor) |
Ibrance (with letrozole) |
HR+, HER2- |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Palbociclib (with fulvestrant) |
Ibrance (with fulvestrant) |
HR+, HER2- |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |
Pegylated Liposomal Doxorubicin |
Caelyx |
HR+, HER2-, HER2+, Triple Negative |
Stage IV (metastatic) |
Health Canada - Approved |
Ribociclib (plus an aromatase inhibitor) |
Kisqali (plus an aromatase inhibitor) |
HR+, HER2- |
Stage IV (metastatic) |
Health Canada - Approved |
Ribociclib (plus aromatase inhibitor) |
Kisquali (plus an aromatase inhibitor) |
HR+, HER2- |
Stage Ib, II, III |
CDA - Under Review |
Ribociclib (plus fulvestrant) |
Kisqali (plus fulvestrant) |
HR+, HER2- |
Stage Ib, II, III |
CDA - Under Review |
Ribociclib (plus fulvestrant) |
Kisqali (plus fulvestrant) |
HR+, HER2- |
Stage IV (metastatic) |
Listed on Provincial Drug Formulary |